Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post–allogeneic HCT
Mohammad Abu Zaid(Indiana University Health), Sung Won Choi(University of Michigan), Corey Cutler(Harvard University), Sophie Paczesny(MUSC Hollings Cancer Center), Joseph H. Antin(Dana-Farber Cancer Institute), Jeffrey Yu(Indiana University Health), Juan Wu(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Cindy Wu(Emmes (United States)), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 89
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases
|Frontiers in Immunology|2017|612